GlassScriptPhysician profile
Layla B Mcdaniel
NPI 1497190524
$13,695.94
in general payments reported to CMS, 2019-2025
32 companies · $3,002 in 2025
The $3,002 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,962 · 2022: $2,354 · 2023: $2,916 · 2024: $3,461 · 2025: $3,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,124 · Education: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,124.06 |
| Education | $254.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,501.03 | 2021-2025 | |
| Amgen INC. | $2,021.25 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Janssen Biotech, INC. | $1,450.18 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $1,135.77 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $1,132.82 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $988.06 | 2022-2025 | Saphnelo |
| Pfizer INC. | $776.55 | 2021-2025 | |
| Glaxosmithkline, LLC. | $519.08 | 2022-2025 | Benlysta |
| Lilly USA, LLC | $437.96 | 2021-2025 | Taltz, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $407.09 | 2021-2025 | Cyltezo, Ofev |
| Mallinckrodt Hospital Products INC. | $301.60 | 2021-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $263.86 | 2021-2025 | Orencia |
| Horizon Therapeutics Plc | $255.38 | 2021-2023 | Krystexxa |
| Radius Health, INC. | $225.24 | 2021-2025 | |
| Sobi, INC | $191.76 | 2021-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $166.67 | 2022-2024 | Strensiq |
| Genzyme Corporation | $131.62 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $123.34 | 2023-2024 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $105.03 | 2021-2023 | Lupkynis |
| Ferring Pharmaceuticals INC. | $99.34 | 2022-2024 | Euflexxa |
| Octapharma USA, INC. | $88.38 | 2023-2024 | Octagam Immune Globulin (Human) |
| Sandoz INC. | $61.98 | 2023-2025 | Hyrimoz, Jubbonti |
| Grifols USA, LLC | $60.17 | 2022-2024 | Xembify |
| Kiniksa Pharmaceuticals, LTD. | $58.26 | 2022-2023 | Arcalyst |
| Genentech USA, INC. | $53.24 | 2024-2025 | Actemra |
| Bioventus LLC | $29.89 | 2025 | Gelsyn-3 |
| Takeda Pharmaceuticals U.S.A., INC. | $26.26 | 2025 | Hyqvia |
| Tersera Therapeutics LLC | $26.23 | 2025 | Quzyttir |
| Pacira Therapeutics, INC. | $22.24 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $21.37 | 2024 | Arcalyst |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.29 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Layla Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.